PMA supplement
P040042 S049: Therapy and Therapy Dual-8 and Safire TX Ablation Catheter
FDA PMA supplement · 30-Day Notice · Irvine Biomedical,Inc.(Ibi)
Key facts
| Original PMA | P040042 |
|---|---|
| Supplement number | S049 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Therapy and Therapy Dual-8 and Safire TX Ablation Catheter |
| Generic name | Catheter, percutaneous, cardiac ablation, for treatment of atrial flutter |
| Applicant | Irvine Biomedical,Inc.(Ibi) |
| Product code | OAD |
| Received date | Feb 25, 2021 |
| Decision date | Mar 24, 2021 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: